The influence of different culture microenvironments on the generation of dendritic cells from non-small-cell lung cancer patients

Archivum Immunologiae et Therapiae Experimentalis

Volumn 55, Issue 6, 2007, Pages 405-415

  Krawczyk, Paweł ^a   Wojas, Kamila ^a   Milanowski, Janusz ^a   Roliński, Jacek ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Cell culture; Dendritic cells; Immunophenotyping; Non small cell lung cancer

Indexed keywords

CD14 ANTIGEN; CD83 ANTIGEN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; HUMAN ALBUMIN; INTERLEUKIN 10; INTERLEUKIN 4; T6 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER STAGING; CELL CULTURE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; LUNG NON SMALL CELL CANCER; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS;

AGED; ANTIGENS, CD; ANTILYMPHOCYTE SERUM; CARCINOMA, NON-SMALL-CELL LUNG; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL SEPARATION; CELLS, CULTURED; CULTURE MEDIA; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INTERLEUKIN-10; INTERLEUKIN-4; LUNG NEOPLASMS; MALE; MIDDLE AGED; MONOCYTES; NEOPLASM STAGING;

EID: 38349089910     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-007-0046-2     Document Type: Article

References (52)

1. Aalamian M., Tourkova I. L., Chatta G. S., Lilja H., Huland E., Huland H., Shurin G. V. and Shurin M. R. (2003): Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J. Urol., 170, 2026-2030.
2. Araki H., Katayama N., Mitani H., Suzuki H., Nishikawa H., Masuya M., Ikuta Y., Hoshino N., Miyashita H., Nishii K., Minami N. and Shiku H. (2001): Efficient ex vivo generation of dendritic cells from CD14+ blood monocytes in the presence of human serum albumin for use in clinical vaccine trials. Br. J. Haematol., 114, 681-689.
3. Avila-Moreno F., Lopez-Gonzalez J. S., Galindo-Rodriguez G., Prado-Garcia H., Bajana S. and Sanchez-Torres C. (2006): Lung squamous cell carcinoma and adenocarcinoma cell lines use different mediators to induce comparable phenotypic and functional changes in human monocyte-derived dendritic cells. Cancer Immunol. Immunother., 55, 599-611.
4. Beadsmoore C. J. and Screaton N. J. (2003): Classification, staging and prognosis of lung cancer. Eur. J. Radiol., 45, 8-17.
5. Bohnenkamp H. R., Burchell J. M., Taylor-Papadimitriou J. and Noll T. (2004): Apoptosis of monocytes and the influence on yield of monocyte-derived dendritic cells. J. Immunol. Methods, 294, 67-80.
6. Boon T. and Van den Eynde B. (2003): Tumour immunology. Curr. Opin. Immunol., 15, 129-130.
7. Buelens C., Verhasselt V., De Groote D., Thielemans K., Goldman M. and Willems F. (1997): Interleukin 10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin 4 and granulocyte/macrophage-colony-stimulating factor. Eur. J. Immunol., 27, 756-762.
8. Chouaib S., Asselin-Paturel C., Mami-Chouaib F., Caignard A. and Blay J. Y. (1997): The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today, 18, 493-497.
9. Coussens L. M. and Werb Z. (2002): Inflammation and cancer. Nature, 420: 860-867.
10. Cranmer L. D., Trevor K. T. and Hersh E. M. (2004): Clinical applications of dendritic cells vaccination in the treatment of cancer. Cancer Immunol. Immunother., 53, 275-306.
11. Dilioglou S., Cruse J. M. and Lewis R. E. (2003): Function of CD80 and CD86 on monocyte- and stem cell-derived dendritic cells. Exp. Mol. Pathol., 75, 217-227.
12. Eljaafari A., Duperrier K., Mazet S., Bardin C., Bernaud J., Durand B., Gebuhrer L., Betuel H. and Rigal D. (1998): Generation of stable monocyte-derived dendritic cells in the presence of high concentrations of homologous or autologous serum: influence of extra-cellular pH. Hum. Immunol., 59, 625-634.
13. Enk A. H., Angeloni V. L., Udey M. C. and Katz S. I. (1993): Inhibition of Langerhans cell antigen-presenting function by IL-10. A role of IL-10 in induction of tolerance. J. Immunol., 151, 2390-2398.
14. Faulkner L., Buchan G. and Baird M. (2000): Interleukin-10 does not affect phagocytosis of particulate antigen by bone marrow-derived dendritic cells but does impair antigen presentation. Immunology, 99, 523-531.
15. Foss F. (2002): Immunologic mechanisms of antitumor activity. Semin. Oncol., 29 (suppl. 7), 5-11.
16. Gabrilovich D. I., Chen H. L., Girgis K. R., Cunningham H. T., Meny G. M., Nadaf S., Kavanaugh D. and Carbone D. P. (1999): Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med., 2, 1096-1103.
17. Gatti E. and Pierre P. (2003): Understanding of cell biology of antigen presentation: the dendritic cell contribution. Curr. Opin. Cell. Biol., 15, 468-473.
18. Gilboa E. (1999): How tumors escape immune destruction and what we can do about it. Cancer Immunol. Immunother., 48, 382-385.
19. Hespanhol V., Queiroga H., Magalhaes A., Santos A.R., Coelho M. and Marques A. (1995): Survival predictors in advanced non-small lung cancer. Lung Cancer, 13, 253-267.
20. Jager E., Jager D. and Knuth A. (2002): Clinical cancer vaccine trials. Curr. Opin. Immunol., 14, 178-182
21. Jakobsen M. A., Moller B. K. and Lillevang S. T. (2004): Serum concentration of the growth medium markedly affects monocyte-derived dendritic cells' phenotype, cytokine production profile and capacities to stimulate in MLR. Scan. J. Immunol., 60, 584-491.
22. Kacani L., Wurm M., Schennach H., Braun I., Andrle J. and Sprinzl G. M. (2003): Immunosuppressive effects of soluble factors secreted by head and neck squamous cell carcinoma on dendritic cells and T lymphocytes. Oral Oncol., 39, 672-679.
23. Kiertscher S. M., Luo J., Dubinett S. M. and Roth M. D. (2000): Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J. Immunol., 164, 1269-1276.
24. Kim D. W., Shyr Y., Shaktour B., Akerley W., Johnson D. H. and Choy H. (2005): Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer, 50, 235-245.
25. Lattime E. C., Mastrangelo M. J., Bagasra O., Li W. and Berd D. (1995): Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol. Immunother., 41, 151-156.
26. Lotze M. T. and Thomas A. W. (2001): Dendritic cells. Second edition. Academic Press, United Kingdom.
27. Marten A., Ziske C., Schottker B., Renoth S., Weineck S., Buttgereit P., Schakowski F., Klingmuller D., Scheffold C., Rucker A., Sauerbruch T. and Schmidt-Wolf I. (2000): Increase in the immunostimulatory effect of dendritic cells by pulsing with serum derived from pancreatic and colorectal cancer patients. Int. J. Colorectal Dis., 15, 197-205.
28. Meidenbauer N., Andreesen R. and Mackensen A. (2001): Dendritic cells for specific cancer immunotherapy. Biol. Chem., 382, 507-520.
29. Menetrier-Caux C., Montmain G., Dieu M. C., Bain C., Favrot M. C., Caux C. and Blay J. Y. (1998): Inhibition of the differentiation of dendritic cells from CD34+ precursors by tumor cells: role of IL-6 and macrophage-colony- stimulating factor. Blood, 92, 4778-4791.
30. Offringa R., van der Burg S. H., Ossendorp F., Toes R. E. and Melief C. J. (2000) Design and evaluation of antigen-specific vaccination strategies against cancer. Curr. Opin. Immunol., 12, 576-582.
31. Onishi H., Morisaki T., Baba E., Kuga H., Kuroki H., Matsumoto K., Tanaka M. and Katano M. (2002): Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer. Clinical Immunol., 105, 286-295.
32. Paglia P. and Guzman C. A. (1998): Keeping the immune system alerted against cancer. Cancer Immunol. Immunother., 46, 88-92.
33. Pedersen A. E., Thorn M., Gad M., Walter M. R., Johnsen H. E., Gaarsdal E., Nikolajsen K., Buuss S., Claesson M. H. and Svane I. M. (2005): Phenotypic and functional characterisation of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. Scan. J. Immunol., 61, 147-156.
34. Pietschmann P., Stockl J., Draxler S., Majdic O. and Knapp W. (2000): Functional and phenotypic characteristic of DC generated in human plasma supplemented medium. Scan. J. Immunol., 51, 377-383.
35. Pinzon-Charry A., Maxwell T. and Lopez J. A. (2005): Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol. Cell. Biol., 83, 451-461.
36. Romani N., Reider D., Heuer M., Ebner S., Kampgen E., Eibl B., Niederwieser D. and Schuler G. (1996): Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods, 196, 137-51
37. Saito H., Tsujitani S., Ikeguchi M., Maeta M. and Kaibara N. (1998): Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br. J. Cancer, 78, 1573-1577.
38. Schuler G., Schuler-Thurner B. and Steinman R. M. (2003): The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol., 15, 138-147
39. Shurin G., Shurin M. R., Bykovskaia S., Shogan J., Lotze M. T. and Barksdale E. M. Jr. (2001): Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res., 61, 363-369.
40. Sietsma H., Nijhof W., Dontje B., Vellenga E., Kamps W. A. and Kok J. W. (1998): Inhibition of hemopoiesis in vitro by neuroblastoma-derived gangliosides. Cancer Res., 58, 4840-4844.
41. Soruri A. and Zwirner J. (2005): Dendritic cells: limited potential in immunotherapy. Int. J. Biochem. Cell. Biol., 37, 241-245.
42. Troy A., Davidson P., Atkinson C. and Hart D. (1998): Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J. Urol., 160, 214-219.
43. Van Engeland M., Nieland L. J., Ramaekers F. C., Schutte B. and Reutelingsperger C. (1998): Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry, 31, 1-9.
44. Vermes I., Haanen C., Steffens-Nakken H. and Reutelingsperger C. (1995): A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V. J. Immunol. Methods, 184, 39-51.
45. Vicari A., Caux C. and Trinchieri G. (2002): Tumor escape form immune surveillance through dendritic cell inactivation. Semin. Cancer Biol., 12, 33-42.
46. Walker P. R., Saas P. and Dietrich P. Y. (1998): Tumor expression of Fas ligand (CD95L) and the consequences. Curr. Opin. Immunol., 10, 564-572.
47. Weynants P., Marchandise F. X. and Sibille Y. (1997): Pulmonary perspective: immunology in diagnosis and treatment of lung cancer. Eur. Respir. J., 10, 1703-1719
48. Wisnivesky J. P., Henschke C., McGinn T. and Iannuzzi M. C. (2005): Prognosis of Stage II non-small cell lung cancer according to tumor and nodal status at diagnosis. Lung Cancer, 49, 181-186.
49. Yannelli J. R., Sturgill J., Foody T. and Hirschowitz E. (2005): The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC). Lung Cancer, 47, 337-350.
50. Yano T., Sugio K., Yamazaki K., Kase S., Yamaguchi M., Ondo K., Yoshino I. and Sugimachi K. (1999): Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer. Lung Cancer, 26, 143-148.
51. Zavadova E., Savary C.A., Templin S., Verschraegen C. F. and Freedman R. S. (2001): Maturation of dendritic cells from ovarian cancer patients. Cancer Chemother. Pharmacol., 48, 289-296.
52. + dendritic cells. Proc. Natl. Acad. Sci. USA, 93, 2588-2592.